Health Care [ 12/12 ] | Biotechnology [ 63/74 ]
NASDAQ | Common Stock
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.
It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases.
In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency.
Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited.
The company was founded in 2003 and is headquartered in Pasadena, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 24 | -1.38 Decreased by -43.75% | -0.55 Decreased by -150.91% |
| May 9, 24 | -1.02 Decreased by -326.67% | -0.16 Decreased by -537.50% |
| Feb 6, 24 | -1.24 Decreased by -217.95% | -0.82 Decreased by -51.22% |
| Nov 29, 23 | -1.02 Decreased by -25.93% | -0.60 Decreased by -70.00% |
| Aug 7, 23 | -0.96 Decreased by -41.18% | -0.65 Decreased by -47.69% |
| May 2, 23 | 0.45 Increased by +9.76% | -0.64 Increased by +170.31% |
| Feb 6, 23 | -0.39 Increased by +35.00% | 0.44 Decreased by -188.64% |
| Nov 28, 22 | -0.81 Decreased by -32.79% | -0.17 Decreased by -376.47% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 0.00 Decreased by -100.00% | -170.79 M Decreased by -65.91% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by -100.00% | -125.30 M Decreased by -357.42% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 3.55 M Decreased by -94.32% | -132.86 M Decreased by -217.77% | Decreased by -3.74 K% Decreased by -5.50 K% |
| Sep 30, 23 | 16.10 M Decreased by -49.02% | -109.68 M Decreased by -27.62% | Decreased by -681.36% Decreased by -150.33% |
| Jun 30, 23 | 15.82 M Decreased by -51.18% | -102.95 M Decreased by -44.62% | Decreased by -650.53% Decreased by -196.21% |
| Mar 31, 23 | 146.27 M Decreased by -3.65% | 48.67 M Increased by +9.71% | Increased by +33.28% Increased by +13.87% |
| Dec 31, 22 | 62.55 M Increased by +127.95% | -41.81 M Increased by +33.50% | Decreased by -66.85% Increased by +70.83% |
| Sep 30, 22 | 31.57 M Decreased by -17.52% | -85.94 M Decreased by -35.61% | Decreased by -272.18% Decreased by -64.42% |